The Viscum album extract Iscador P does not cause an autocrine interleukin-6 loop in B-Non-Hodgkin's lymphoma cell lines

Onkologie

Volumn 28, Issue 8-9, 2005, Pages 415-420

  Hugo, Frauke ^a   Dittmar, Thomas ^a   Treutler, Eva K ^a   Zänker, Kurt S ^a   Kuehn, Jürgen J ^b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b Lukasclinic Arlesheim ^*  (Switzerland)

Author keywords

Interleukin 6; Non Hodgkin's Lymphoma; Viscum album extract

Indexed keywords

INTERLEUKIN 6; ISCADOR P; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT;

ARTICLE; CANCER CELL CULTURE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INCUBATION TIME; LYMPHOMA CELL LINE; MEDICINAL PLANT; NONHODGKIN LYMPHOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VISCUM ALBUM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; AUTOCRINE COMMUNICATION; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-6; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; PARACRINE COMMUNICATION; PLANT EXTRACTS; PLANT PROTEINS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 27644532725     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086343     Document Type: Article

References (16)

1. Nikolai G, Friedl P, Werner M, Niggemann B, Zänker KS: Effect of a mistletoe extract (Iscador QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices. In Vitro Cell Dev Biol Anim 1997;33:710-716.
2. Kuehn JJ: Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non-Hodgkin lymphoma. Dtsch Med Wochenschr 1999;124:1414-1418.
3. Kuehn JJ: Mistletoe therapy in malignant lymphomas: New findings and observations from a prospective series of case histories of patients with follicular non-Hodgkin's lymphoma; in Scheer R (Hrsg): Die Mistel in der Tumortherapie. Essen, KVC, 2005, in press.
4. Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ: Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 1990;50:3322-3326.
5. Kovacs E, Kuehn JJ: Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affect these parameters? Biomed Pharmacother 2002;56:152-158.
6. Rose-John S: Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol 2003;50:603-611.
7. Kishimoto T: The biology of interleukin-6. Blood 1989;74:1-10.
8. Rose-John S, Neurath MF: IL-6 trans-signaling: the heat is on. Immunity 2004;20:2-4.
9. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S: Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268:160-167.
10. Kurzrock R: Cytokine deregulation in hematological malignancies: Clinical and biological implications. Clin Cancer Res 1997;3:2581-2584.
11. Gaillard JP, Liautard J, Klein B, Brochier J: Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines. Eur J Immunol 1997;27:3332-3340.
12. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M: Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993;53:2118-2122.
13. Kato H, Kinoshita T, Suzuki S, Nagasaka T, Hatano S, Murate T, Saito H, Hotta T: Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1998;29:71-79.
14. Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zänker KS, Brandt BH: Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. Faseb J 2002; 16:1823-1825.
15. Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, Weidmann E: In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001;86:485-493.
16. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 2002;87: 33-43.